Cytokinetics Attracts Big Pharma Interest Amid Aficamten’s Phase III Success
Cytokinetics (NASDAQ: CYTK), a specialist in cardiovascular diseases, is reportedly attracting interest from multiple Big...
Novartis
Alphabet’s Isomorphic Labs Inks Pharma Partnerships with Eli Lilly and Novartis
Isomorphic Labs, a drug discovery company under the umbrella of Google’s parent group Alphabet (NASDAQ:...
Novartis’s Cosentyx Secures Additional Indication for Psoriatic Arthritis in China
Swiss pharmaceutical giant Novartis (SWX: NOVN) has announced that its drug Cosentyx (secukinumab), which targets...
International Society for Cell & Gene Therapy Comments on FDA’s CAR-T Investigation
The International Society for Cell & Gene Therapy (ISCT) has published a statement addressing the...
Novartis Strikes Deal with Argo Biopharma for Global Rights to siRNA Drug Candidates
Argo Biopharma, a Shanghai-based developer of small interfering RNA (siRNA) drugs, has secured a licensing...
Novartis to Fully Acquire SanReno Therapeutics to Expand Kidney Drug Portfolio in China
Novartis (NYSE: NVS), a Swiss pharmaceutical giant, has announced plans to acquire the remaining shares...
GenScipt Subsidiary Legend Biotech Finalizes Licensing Deal with Novartis for DLL3 CAR-T Therapies
GenScipt Biotech Corp., a China-based Contract Development and Manufacturing Organization (CDMO) (HKG: 1548), has announced...
FDA Prioritizes Roche’s Xolair for Food Allergy Indication Extension Ahead of Q1 Decision
The U.S. Food and Drug Administration (FDA) has prioritized Roche’s (SWX: ROG) indication extension filing...
Jiangsu Hengrui Pharmaceuticals Wins NMPA Approvals for SLE and Lymphoma Drug Candidates
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced that...
Novartis Reports Kisqali Success in Reducing Recurrence Risk in Early Breast Cancer
Novartis (NYSE: NVS) has announced an update on the late-stage trial for its CDK4/6 inhibitor...
Novartis’ Fabhalta Wins FDA Nod as First-in-Class Treatment for Paroxysmal Nocturnal Hemoglobinuria
Swiss pharmaceutical giant Novartis (NYSE: NVS) has secured regulatory approval from the US Food and...
Novartis Invests USD 86.4 Million in New Radiotherapy Facility in China
Swiss pharmaceutical giant Novartis (NYSE: NVS) has invested over 600 million Chinese yuan (approximately USD...
CAR T-Cell Therapy Stocks Plunge as FDA Investigates Cancer Reports Linked to Treatments
Shares of Chimeric Antigen Receptor (CAR) T cell therapy companies plummeted on November 28, 2023,...
Novartis Acquires HDAC6 Inhibitor CKD-510 from CKD Pharmaceutical in a $1.31 Billion Deal
Swiss pharmaceutical major Novartis (NYSE: NVS) announced last week that it has struck a deal...
Novartis Pharma AG Partners with Legend Biotech Corp. for CAR-T Therapies in $1.1 Billion Deal
China-based Legend Biotech Corp., (NASDAQ: LEGN) has secured a second multinational partnership for its chimeric...
Chiesi Farmaceutici and Shanghai Pharmaceutical Partner on Distribution at CIIE
Among the series of deals secured by multinational corporations at the 6th China International Import...
Novartis’ Remibrutinib Meets Milestones in Late-Stage Chronic Spontaneous Urticaria Studies
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that two late-stage studies for its Bruton’s...
Sandoz Enters Euro Debt Market with $2.1 Billion Eurobond Issuance
Switzerland-based Sandoz (SWX: SDZ), a leader in the generics and biosimilars market, has successfully entered...
Novartis’ Cosentyx Gains FDA Approval for Hidradenitis Suppurativa Treatment
The US Food and Drug Administration (FDA) has issued regulatory approval for Novartis’ (NYSE: NVS)...
Novartis Announces Positive Interim Results for Atrasentan in IgA Nephropathy Phase III Study
Novartis (NYSE: NVS), a global healthcare company, has released interim results from an ongoing Phase...